



December 18, 2024

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Scrip Code: 544029

Listing & Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, “G” Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
Symbol: GANDHAR

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Further to our intimation dated September 27, 2024 on the inspection conducted by the United States Food & Drug Administration (USFDA) at our Company’s manufacturing facility located at Taloja, we wish to inform you that the Company has received the Establishment Inspection Report (EIR). The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded the inspection is “closed” under 21 CFR 20.64 (d)(3).

This is for your information and you are requested to kindly take the same on record.

Thanking You,

Yours Faithfully

For **Gandhar Oil Refinery (India) Limited**

Jayshree Soni
Company Secretary and Compliance Officer
Mem. No.: FCS 6528